Comparator advice is "serious, explicit and non-ambiguous," warns German drug HTA body
This article was originally published in SRA
Executive Summary
Germany's G-BA, the body in charge of the country's AMNOG early benefit assessments for new drugs, says that while its initial advice may be non-binding, it nevertheless expects pharmaceutical companies to "respect" its recommendations1.